Pfizer, Inc.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S carries a market capitalization of 194.24B, placing it among publicly traded companies globally. Its enterprise value stands at 267.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S has 18.02B shares outstanding.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S trades at a trailing price-to-earnings ratio of 31.54. The price-to-sales ratio is 2.15, and the price-to-book ratio stands at 1.61.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S trades at an EV/EBITDA multiple of 16.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 39.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 267.76B versus a market cap of 194.24B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 73.92, indicating elevated leverage, while an interest coverage ratio of 4.22 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S posted a return on equity (ROE) of 4.98, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.13, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.18M in revenue per employee across its workforce of 76,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S recorded an income tax benefit of -232.75M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 5.97B, leaving 6.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 12.54, while the 200-day moving average is 11.95.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S generated 90.40B in revenue and converted that into 6.15B in net income, yielding earnings per share of 0.34. EBITDA reached 16.17B, while operating income came in at 24.15B.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S holds 16.60B in cash and equivalents against 89.69B in total debt, resulting in a net debt position of 88.30B. Total book value stands at 120.90B, with working capital of 12.36B providing operational flexibility.

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S produced 19.02B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.43B in capital expenditures, free cash flow totaled 15.59B - equivalent to 0.87 per share.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S posted a gross margin of 73.18, reflecting its pricing power and cost economics. The operating margin of 26.72 and net profit margin of 6.80 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S paid dividends of 0.77 per share. The dividend payout ratio of 221.98 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.01, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S shareholders.

As of June 30, 2026, Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S has an Altman Z-Score of 4.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.